NASDAQ:MYNZ

Mainz Biomed B.V.


Mainz Biomed BV is engaged in developing molecular genetic diagnostic solutions for life-threatening conditions. It’s main product Coloalert is a kit that includes a stool collector and shipping instructions to return the kit through regular mail to their local lab for testing and results.

In The Press

Mainz Biomed B.V. News

May 31, 2023

Mainz Biomed Expands Commercial Footprint into Poland

Read More
May 24, 2023

Mainz Biomed Processes First Patients from Colorectal Cancer Screening Campaign Through its Corporate Health Portal in Partnership with Zöeller-Kipper

Read More
May 16, 2023

Mainz Biomed Announces First Quarter 2023 Financial Results and Provides Corporate Update

Read More
May 10, 2023

Mainz Biomed Partners with Microba Life Sciences for the Development of PancAlert

Read More
May 03, 2023

Mainz Biomed Announces Addition of Eurofins GeLaMed to its Growing Network of Lab Partners

Read More
May 01, 2023

Mainz Biomed to Participate in Digestive Disease Week 2023

Read More
Apr 27, 2023

Mainz Biomed to Commence Quarterly Reporting and Present at Equity Forum Spring Conference 2023 in Frankfurt, Germany

Read More
Apr 26, 2023

Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert® Commercialization in Spain and Portugal

Read More